Home Search Contact Print Sign In
Products Services Resource Center Ordering About Exiqon
microRNA Research
mRNA & lncRNA Research
DNA Research
Custom LNA™ Oligos
LNA™ Phosphoramidites
RNA Isolation
Microarray Analysis
Real-time PCR
Northern Blotting
In Situ Hybridization
Functional Analysis
RNA Isolation
Microarray Analysis
Real-time PCR
In Situ Hybridization
SNP Detection
Microarray Analysis
In Situ Hybridization
RNA Isolation Services
microRNA PCR Services
Sequencing Services
Custom Pharma Service
Application Stories


Exiqon A/S was founded on 1 November 1995 and became operational in the spring of 1996. At the end of 1997, Exiqon secured the exclusive rights to the LNA™ (Locked Nucleic Acid) technology from the Danish inventors of the technology. Exiqon developed the LNA™ technology, including procedures for large-scale manufacturing and a large number of applications for the LNA™ technology, which have all been patented.

In 1999, Cureon A/S was founded as a subsidiary of Exiqon for the purpose of exploiting the therapeutic potential of the LNA™ technology. Cureon A/S was later merged with Panteco A/S, thereby forming the company Santaris Pharma A/S. Exiqon has since sold its stake in Santaris Pharma A/S. Santaris Pharma A/S was acquired by F. Hoffmann-La Roche AG in 2014. Exiqon has retained all the rights to the LNA™ technology, except for the therapeutic applications of the LNA™ technology.

In 2003, Exiqon developed and implemented the product oriented strategy for its Life Sciences division. The first research product, Universal ProbeLibrary™, was launched in the spring of 2004. In 2005, Exiqon formed a strategic alliance with Roche Diagnostics for selling the Universal ProbeLibrary™.

In 2006, Exiqon established a subsidiary in the United States and a US sales organization.

In June 2016, Exiqon was acquired by QIAGEN. We are excited to bring Exiqon's unique products and services into the QIAGEN portfolio.

microRNA product range

Exiqon's main product range (miRCURY™) was launched in 2005, including LNA™-enhanced tools for microRNA analysis including Arrays, Detection probes, Inhibitors and qPCR assays. Since then, the miRCURY™ product range has been expanded to encompass the entire microRNA analysis workflow from sample preparation to expression analysis, detection and a range of tools for functional analysis (inhibitors, mimics, target site blockers) both in vitro and in vivo.

In 2009, Exiqon successfully launched the 2nd generation miRCURY LNA™ Universal RT microRNA PCR System. This system is the most sensitive and specific microRNA expression profiling platform currently available on the market, and allowed Exiqon to gain significant market share in the fast growing market segment for qPCR expression analysis of microRNA.

In 2016 Exiqon took advantage of their expertise in microRNA and small RNA sequencing to launch the first microRNA NGS sample QC kits on the market.

RNA product range

Since 2012, Exiqon has extended its range of LNA™-based products to include tools for the analysis of mRNA and long non-coding RNA. Initially, Exiqon offered LNA™ detection probes and custom LNA™ qPCR assays for mRNA and lncRNA. In 2013, Exiqon launched Antisense LNA™ GapmeRs for potent and specific knockdown of mRNA and lncRNA, and in 2015 the ExiLERATE LNA™ qPCR system was launched. In 2016 Exiqon launched the first probe-based kit for quantification of NGS libraries prior to sequencing on Illumina® instruments.

Exiqon Services

Exiqon began offering microRNA expression profiling Services using the miRCURY LNA™ microRNA Arrays, and founded its Services facility in Vedbaek, Denmark, in 2006. Over the years, Exiqon Services has increased its service offering to provide a complete sample-to-answer solution including isolation of RNA/exosomes, microRNA qPCR analysis, Next Generation Sequencing (of microRNA, small RNA, mRNA and whole transcriptome), and comprehensive data analysis.

Exiqon Diagnostics

Exiqon took the first steps towards using the existing LNA™ products for microRNA analysis in diagnostic applications, and the identification of microRNA biomarkers in cancer was initiated in 2006 by Exiqon Diagnostics. In 2008, Exiqon Diagnostics began their pioneering work in the area of microRNA cancer biomarker discovery in liquid biopsies (serum, plasma and urine and other biofluids). In 2010 Exiqon published the first clinical data from one of our diagnostic programs and also granted a product-specific license to Becton, Dickinson and Company to use Exiqon's proprietary LNA™ technology in defined diagnostic products for certain infectious diseases.
  Privacy   Sitemap   Legal